Clinical Trial Update: Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial is evaluating the combination of ibrutinib and palbociclib in patients with previously treated mantle cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Ibrutinib (ibrutinib)
• Palbociclib (palbociclib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Mantle Cell Lymphoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING